Cryopreserved leukopaks

Consistent, ready-to-use immune cell starting material for cell therapy development. By decoupling collection from use, cryopreserved leukopaks enable on-demand access to the same donor material, reducing dependence on donor availability and standardizing workflows across multiple sites.

Product Overview

Cryopreserved leukopaks are a high-quality source of immune cells preserved through controlled freezing processes to preserve cell viability and functionality upon thawing. Backed by rigorous safety standards and a robust European collection infrastructure, these leukopaks offer the consistency and scalability required to advance processes from research to manufacturing.



Derived from leukapheresis collections, cryopreserved leukopaks contain high yields of viable mononuclear cells, including T cells, NK cells, and other key immune subsets. Cryopreservation enables longterm storage and repeatable use of the same donor material, reducing dependence on donor availability and collection timing. This supports workflow standardization, comparability studies, inventory management, and consistent execution across multiple experiments, manufacturing runs and development sites.



Backed by a large and diverse donor network and supported by robust quality systems and documentation, our cryopreserved leukopaks offer reliable access to immune cell material while facilitating logistics, global distribution, and multi-site studies.

Uses of leukopaks

Isolation of peripheral blood mononuclear cells (PBMCs) populations such as T cells, NK cells and monocytes

Activation, genetic engineering, and expansion of immune cells

Process development, optimization, and comparability studies

Donor selection, cell banking, and allogeneic platform development

Key Features

Donor Sourcing & Characterization

  • Grifols sources leukopaks through a broad and well‑established donor network, enabling access to diverse immune cell compositions and flexible sourcing options aligned with cell therapy development needs.
  • Donors are well characterized, allowing selection based on defined criteria such as age, sex, HLA type, CMV status, blood type, and immunophenotyping.
  • Grifols enables donor continuity through recallable donors, allowing repeat collections from the same donor. In addition, established back‑up donor scheduling in each donation ensures reliable, on‑time availability and delivery for each collection.
  • All donors undergo stringent screening and continuous monitoring, as leukopak donors are sourced from Grifols’ established plasma donor network, which provides extensive historical data, resulting in a higher level of safety, consistency, and traceability.

Cryopreserved Leukopak Core Characteristics

  • Cryopreserved using validated controlled‑rate freezing protocols and optimized cryoprotectant conditions to preserve cell viability and functional performance post‑thaw.
  • Processed into multiple cryobags (typically 4–6 units per leukopak), enabling flexible use across experiments while maintaining consistent cellular composition.1,2
  • Each 50ml unit contains ≥2.5 billion total cells.
  • Packaged in validated cryogenic storage bags compatible with closed-system handling, ensuring product integrity and facilitating safe manipulation.

1. Gómez I, Schaffer JM, Winterstein K, et al. Optimizing cell sourcing for cell therapy by reducing donor variability with recallable leukopak donors for enhanced standardization. Cytoherapy. 2025;27(5 Suppl):S141

2. Gómez-Gràcia I, Gonnermann D, Paschold L, et al. Donor demographics and leukopak consistency: yield and composition as operational benchmarks for cell-therapy starting materials. Curr Res Transl Med. 2026;74(3):103591
 

Quality Grade

Cryopreserved leukopaks are currently provided as Research Use Only (RUO) material, suitable for early-stage research, assay development, and process optimization in cell therapy workflows.

RUO (Research Use Only)

Key characteristics:

  • Cryopreserved under controlled conditions
  • High post-thaw performance: ≥90% viability and ≥80% recovery
  • Viral marker testing performed on each donation
  • Documentation suitable for research and non-clinical use

Regulatory & Documentation Support

Robust documentation and analytical data are provided to support donor characterization, traceability, and quality assessment in cell therapy workflows.

  • Certificate of analysis (CoA)
  • Quality control (QC)
  • Viral marker testing performed on every donation
  • Complete blood count and cell concentration analysis included
  • Optional immunophenotyping: CD3, CD4, CD8, CD14, CD19, CD56 (on demand)

Product Formats

Each cryopreserved leukopak is derived from a single fresh leukopak and aseptically processed into multiple cryobags. This format enables repeated use of material from the same donor collection while providing scheduling flexibility and efficient inventory management.

Product
 

Derived from a single fresh leukopak and aseptically processed into multiple cryobags, enabling decoupling of collection from use.

Best suited for: process development, comparability studies, validation activities, and repeated use of the same donor material.

Key features
  • Up to six cryobags per leukopak 
  • Each 50 mL cryobag contains ≥2.5 billion total cells 
  • Consistent material derived from a single donor collection 
  • Suitable for staged project execution and repeated use of the same donor material.
  • Available individually or as complete leukopak sets
Product   Key features

Standard Cryobag Format

Derived from a single fresh leukopak and aseptically processed into multiple cryobags, enabling decoupling of collection from use.

Best suited for: process development, comparability studies, validation activities, and repeated use of the same donor material.

  • Up to six cryobags per leukopak 
  • Each 50 mL cryobag contains ≥2.5 billion total cells 
  • Consistent material derived from a single donor collection 
  • Suitable for staged project execution and repeated use of the same donor material.
  • Available individually or as complete leukopak sets

Available for Order

Configure cryopreserved leukopaks online according to your donor and product requirements and receive a personalized quotation.

Cell Therapy Applications

CAR‑T Cell Therapies

Cryopreserved leukopaks provide consistent T-cell starting material, enabling repeated process development and scalable CAR-T manufacturing workflows while reducing dependence on collection timing.

TCR‑Engineered Cell Therapies

Support receptor engineering workflows with standardized T-cell inputs that improve experimental consistency across runs.

NK‑Cell Immunotherapies

Provide NK cells suitable for activation and expansion, with cryopreservation enabling repeat use and process.

Allogeneic (Off the Shelf) Immune Cell Therapies

Enable donor banking, batch consistency, inventory management, and long-term storage capabilities that support scalable allogeneic therapy platforms.

Why Grifols Bio Supplies

Pharma‑to‑Pharma

Backed by decades of plasma-derived product and biopharmaceutical manufacturing experience, Grifols Bio Supplies applies pharma-grade manufacturing discipline, controlled processes, and rigorous documentation to deliver cell therapy developers a high-quality starting material and operational support.

Worldwide Donor Network

Access to a large, diverse, and well-characterized donor network supported by multiple collection sites in the US and Europe, enabling broader immune-cell sourcing options and robust cell therapy process development.

Quality & Safety

Our leukopak donors are sourced from Grifols’ established plasma donor network, enabling stringent donor screening, continuous monitoring, and access in many cases to extensive donor historical data. Combined with controlled processing and comprehensive testing, this provides an additional layer of safety and traceability.

High-Yield Immune Cell Starting Material

Leukapheresis-derived leukopaks provide large quantities of viable mononuclear cells enabling efficient downstream processing and reducing the need for multiple collections.

Reliable Global Supply

A global infrastructure designed to support scalable, long‑term supply for cell therapy programs.

Regulatory & Documentation Support

Comprehensive documentation aligned with donor characterization, traceability, and regulatory expectations, supporting cell therapy developers as they advance toward GMP-ready processes.

Product Resources

Explore additional technical resources and product information to support your leukopak sourcing and cell therapy development activities.

Product Brochure

Download

Cell Therapy Brochure

Download

Cell Therapy Infographic

Download

Cryopreserved Leukopkas Thawing Protocol 

Download

Related Cell Therapy Products

To support cell therapy manufacturing, complementary products are available to help protect and stabilize cell quality during critical processing steps, from upstream handling through downstream formulation.

Fresh leukopaks

A leukapheresis-derived starting material rich in immune cells, including T cells, NK cells, and other PBMC populations, collected from a single donor and delivered fresh for immediate use, supporting high cell viability and yield for time-sensitive cell therapy workflows.

Human serum albumin

A versatile plasma-derived protein with strong stabilizing properties that help maintain cell viability, prevent aggregation, and improve cell retention during cell handling and processing, including culture, washing, and cryopreservation.

Human male AB serum

A widely used cell culture supplement that offers a balanced mix of growth factors, hormones and attachment agents minimizing immunological risk and enhancing biological compatibility supporting improved cell viability and expansion.

Have questions before requesting a quote?

Contact our team for product information, technical guidance, or assistance selecting the right solution for your application.

FAQs

A cryopreserved leukopak is a leukapheresis‑derived product in which immune cells are frozen under controlled conditions to preserve their viability and function after thawing.
They are valuable in cell therapy because they provide a consistent and flexible cell source, enabling reproducible process development, simplified logistics, and reduce dependence on donor availability and collection timing across workflows.

Each cryopreserved leukopak is processed into up to six cryobag with each cryobag containing ≥2.5 billion total mononuclear cells, and having ≥90% viability and ≥80% recovery post thawing. 

Leukopaks are cryopreserved within 24 hours of collection to support cell viability and post-thaw performance.

Customers can request specific donor attributes, such as age range, sex, race, CMV status, HLA typing, and other relevant criteria depending on their project needs and region collection (USA or EU).

Cryopreserved leukopaks are shipped from our European facilities and can be delivered across the United States, Europe, and Asia.

Cryopreserved leukopaks provide greater flexibility by allowing collection and use to be separated in time. This enables long-term storage, repeat use of material from the same donor collection, workflow standardization, comparability studies, and simplified logistics across research and manufacturing programs.

You can order fresh leukopaks in two ways:
1. Request a Quote (RFQ) 
Use our RFQ tool to configure fresh leukopaks based on your donor and product requirements and submit your request for a personalized quotation.
2. Contact Us 
Complete our Contact Us form to discuss your project with our team, and we'll help identify the best leukopak solution for your needs.
For the fastest experience, we recommend using the RFQ tool, as it allows our team to receive your requirements upfront and respond with a tailored quote more efficiently.